



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

# Infectious Diarrhea

## Pathogenesis and Risk Factors

J. ROBERT CANTEY, M.D.

*Charleston, South Carolina*

Our understanding of the pathogenesis of infectious, especially bacterial, diarrhea has increased dramatically. New etiologic agents, mechanisms, and diseases have become known. For example, *Escherichia coli* serogroup 0157 is now known to cause acute hemorrhagic colitis. Also, *E. coli* serogroups that produce Shiga toxin are recognized as etiologic agents in the hemolytic-uremic syndrome. The production of bacterial diarrhea has two major facets, bacterial-mucosal interaction and the induction of intestinal fluid loss by enterotoxins. Bacterial-mucosal interaction can be described in stages: (1) adherence to epithelial cell microvilli, which is often promoted by or associated with pili; (2) close adherence (enteroadherence), usually by classic enteropathogenic *E. coli*, to mucosal epithelial cells lacking microvilli; and (3) mucosal invasion, as with *Shigella* and *Salmonella* infections. Further large strides in understanding infectious diarrhea are likely with the cloning of virulence genes if additional host-specific animal pathogens become available for study.

The past few years have witnessed an explosion in the number of publications exploring many aspects of infectious diarrhea. This review will examine the present status of our understanding of pathogenesis.


### GUT BARRIERS TO INFECTIOUS AGENTS

Nonspecific host barriers to infection are summarized diagrammatically in **Figure 1**. The first barrier to be encountered in the passage of the infectious agent from the oropharynx is gastric acidity, which is sufficient to kill or inhibit many Enterobacteriaceae [1]. Gut motility is important in preventing infectious agents from approaching the mucosa, as is evident from the fact that animals given opiates to decrease motility experience diarrhea with infectious agents to which they would not ordinarily be susceptible [2]. The "unstirred water layer," a zone of retarded diffusion of solutes in the intestine [3], could slow the movement of infectious agents toward the mucosal epithelium. The layer of intestinal mucus would also interfere. Beneath the mucous layer is the glycocalyx, which is anchored in the plasmalemma of the epithelial cell and consists of long strands of protein with carbohydrate side chains [4]. Once the infectious agent penetrates the glycocalyx, it could adhere directly to the plasmalemma or invade the epithelial cell.

### PATHOGENESIS OF VIRAL INFECTIONS OF THE GASTROINTESTINAL TRACT

Infections due to rotavirus, Norwalk virus, and coronavirus are the best studied of the viral enteritides. Viral particles can be found in absorptive epithelial cells of the upper small bowel during rotavirus and coronavirus

From the Veterans Administration Medical Center and the Department of Medicine, Medical University of South Carolina, Charleston, South Carolina. Requests for reprints should be addressed to Dr. J. Robert Cantey, Veterans Administration Medical Center, 109 Bee Street, Charleston, South Carolina 29403.



**Figure 1.** Schematic representation of host barriers faced by intestinal pathogens. MEC = mucosal epithelial cell.

infections [5–7]. The jejunum is the major site of infection, but the ileum may also be involved [8–11]. Intestinal villus shortening, crypt hypertrophy, increased epithelial cell turnover, and acute inflammation all occur [7,8,10–15]. Epithelial cell microvilli are shortened, blunted, and decreased in number [7,14,15]. The deficiency of brush border disaccharidase and sodium/potassium-ATPase activity that is thought to produce diarrhea in viral gastrointestinal infections is a reflection of the increase in immature crypt-type enterocytes on the villus epithelium [8–10,13,15]. Little is known about viral-mucosal epithelial cell interaction, except that specific receptors on the epithelial cell seem necessary in Norwalk virus diarrhea [16].

#### **PATHOGENESIS OF BACTERIAL INFECTIONS OF THE GASTROINTESTINAL TRACT**

Bacterial-mucosal interaction may be divided into several stages: adherence to intact microvilli, adherence to the surfaces of epithelial cells that have lost their microvilli, termed “enteroadherence,” and invasion of the mucosal epithelial cells. There are likely other stages, but examples are not well documented. Current evidence indicates that bacteria that produce diarrhea also synthesize some form of enterotoxin. The following comments focus on the bacterial-mucosal interactions that are best understood.

**Bacteria That Are Confined to the Lumen. Adherence to intact microvilli:** The mechanisms and relevant surface structures of the interaction of *Vibrio cholerae* with human and animal intestinal epithelium remain poorly understood, partly because study has been hampered by the lack of pathogenicity of *V. cholerae* in animals. Such studies as have been done indicate that *V. cholerae* ad-

heres to gut epithelial cells in order to produce diarrhea [17–22]. Surface structures important to adherence are unknown. Although it may adhere, *V. cholerae* type 01 does not invade. Ultrastructural studies of human and animal cholera reveal minimal changes in gut epithelial cells and microvillus border [23–25].

More is known about the pathogenesis of enterotoxigenic *Escherichia coli* diarrhea, as host-specific animal pathogens—and, thus, good animal models—are readily available. Enterotoxigenic *E. coli* can be seen adhering to intact microvilli in ultrastructural studies [26]. Those that cause diarrhea in pigs were the first bacteria demonstrated to possess pilus (fimbrial) adherence ligands [27]. The pilus or fimbria [28–31] is a filamentous surface protein that is 0.5 to 2  $\mu\text{m}$  long, approximately 7 nm in diameter, and composed of 15 to 20 kilodalton repeating units with an aggregate molecular weight in excess of one million. There are two major groups of pili. The first is the common or type 1 pilus that is associated with mannose-sensitive nonspecific adherence to red cells or various other cells [28,31]. The second group includes pili thought to mediate adherence to specific cells in specific species, the so-called colonization factor antigens [32]. The genes of the type 1 pili usually reside on the bacterial genome, whereas the genes for the latter pili usually reside in plasmid DNA. The porcine *E. coli* pili were initially believed to be thermolabile polysaccharide antigens and were labeled K88 antigens [33]. The ability of K88-positive enterotoxigenic *E. coli* to cause diarrhea in pig(lets) was shown to be increased by the K88 antigen. Since that time, other adherence pili of enterotoxigenic *E. coli* have been described, including K99 in calves, lambs, and occasionally piglets [34–36], 987 in pigs [35,37,38], F41 in calves, lambs, and piglets [39–42], and CFA I and II in humans and infant rabbits [32,43–45]. The K88 pilus increases adherence in the upper small bowel, whereas the K99 and 987 pili increase adherence in the distal small bowel. Increased *in vivo* adherence and diarrheal attack rate is correlated with *in vitro* adherence to gut mucosal epithelial cells and partially purified gut epithelial cell brush border [46–52].

Pilus adherence ligands are limited in variety in animals, in contrast to the human species, in which a large stable of ligands still does not account for the majority of enterotoxigenic *E. coli*. The lack of a completely satisfactory *in vitro* adherence assay for human-associated species of enterotoxigenic *E. coli* has led to an array of assays and different, often overlapping, pilus typing schemes (Table I). The two major schema are those of Evans et al [43,44] and Deneke et al [53–55].

My reasons for referring to adherence as pilus-associated, rather than being *due to* pili, are several. First, consider Table I. Human strains of *E. coli* adhere to animal tissues [43,44], and animal strains adhere to human tissues [52,56]. If bacteria can show preference for proximal or distal small bowel, why do they show lack of specificity

concerning species? Perhaps the adherence assays are measuring a characteristic that is not related to adherence *in vivo* in the preferred species. Additionally, there are major differences among laboratories, which may reflect shortcomings of the assays. For example, in one study, K88-positive bacteria but not K99-positive bacteria adhered to human ileostomy cells [56]. In a different laboratory, K99-positive but not K88-positive bacteria adhered to human jejunal cells [52].

Another reason for concern is the following. Studies with both human and animal strains of bacteria have used bacteria whose virulence characteristics, such as pili, have been deleted by exposure of the parent bacterium to nonselective mutagens. In no case has the mutant been carefully examined as to possible associated changes in outer membrane proteins, ability to grow in the anaerobic environment of the gut, and other variables. The same can be said for transfer of pilus-associated plasmids. The plasmids are often quite large, and they contain more genes than would likely be necessary for pilus synthesis. How might these additional genes change the recipient bacterium?

**Enteroadherent bacteria:** *E. coli*, in humans, usually members of the classic enteropathogenic *E. coli* serogroups that adhere closely to epithelial cells lacking microvilli, have been termed enteroadherent [57] or enteroeffacing [58]. The phenomenon of close adherence of enteropathogenic *E. coli* was first reported in cesarian-delivered monocontaminated pigs given a  $10^{11}$  inoculum of serogroup O55 *E. coli* [59]. The histopathologic features and characteristics of the disease were reported in detail and postulated to be a previously unrecognized mechanism of *E. coli* diarrhea in rabbits given a  $10^6$  inoculum of rabbit-specific enteroadherent *E. coli* strain RDEC-1 [60–62]. Similar histopathologic findings have since been reported in humans infected with enteropathogenic *E. coli* serogroups O111, O119, and O125 *E. coli* [63–65]. The bacteria first interact with intact microvilli of mucosal epithelial cells of the distal ileum and colon [62]. The microvilli form round bodies and disappear [62]. The bacteria then adhere closely (approximately 11 nm [61]) to the epithelial cell surface, which tends to cup the bacterium by forming pedestal-like structures [62,64] (**Figure 2**). Invasion of the epithelial cells does not occur. The RDEC-1 strain adheres first to M cells in the epithelium of the Peyer's patches [57], but it is not known whether human strains do the same. In an autopsy series, infants dying of serogroup O111 *E. coli* diarrhea had lymphoid hyperplasia, but close adherence of bacteria was not noted [66].

Human strains of enteropathogenic *E. coli* have been found to adhere to Hep-2 and more recently HeLa cells in culture with greater frequency than non-enteropathogenic *E. coli* strains [67–69], providing investigators with a useful diagnostic and epidemiologic tool. Serotype O111 and O119 *E. coli* strains isolated from patients whose jejunal biopsy specimens revealed typical close adherence are

**TABLE I Adherence Pilus Serogroups of Human Enterotoxigenic *E. coli* Strains and Assays Used for Their Detection**

<b>Adherence pill of Evans et al</b>	
CFA I	
	Infant rabbit intestine [43] <sup>†</sup>
	Intestinal epithelial tissue culture <sup>†</sup> [51]
	Jejunal cell [52]
	Ileal brush border [49]
	Duodenal cell [50]
CFA II	
	Infant rabbit intestine [44]
	Jejunal cell [52]
	Duodenal cell [50]
<b>Serogroups of Thorne and Deneke [53–55]</b>	
Serogroup I	
	Buccal epithelial cells
Serogroup II (CFA I)	
	Buccal epithelial cell
	Ileostomy cell
Serogroup III (CFA II)	
	Buccal epithelial cell
	Ileostomy cell
Additional serogroups not shown	


<sup>†</sup>References for assays.

<sup>†</sup>Tissues or cells from humans unless otherwise stated.

among strains adhering to Hep-2 or HeLa cells [64,65]. As a result of this correlation, Hep-2 cell adherence has come to be accepted as an *in vitro* characteristic of enteroadherent *E. coli*. Not all enteroadherent *E. coli* associated with diarrhea are enteropathogenic *E. coli* serotypes, at least in the case of traveler's diarrhea [70].

The adherence ligand of the RDEC-1 strain is plasmid-mediated, highly specific for the rabbit, and is either a pilus structure or is on the same plasmid and cotransferred with pilus expression [71]. An idea of the forces involved in the early stage of adherence of the RDEC-1 strain to intact microvilli may be gathered by studies in which piliated RDEC-1 strain bacteria caused much larger rabbit ileal cell brush borders to aggregate in large visible clumps [72]. Human strains of enteroadherent *E. coli* do not appear to be piliated under the culture conditions used thus far [73]. RDEC-1 pili are expressed in one medium and suppressed in another [62,71,72], so it may be a matter of finding the right set of culture conditions. The ability of human enteroadherent *E. coli* to adhere to Hep-2 cells is associated with and can be transferred to another bacterium with a large plasmid [74].

**Invasive Bacteria.** The pathogenesis of shigellosis has been the subject of much research, particularly by Formal and his colleagues at Walter Reed Army Institute of Research [75–77]. The *Shigella* bacterium adheres to and invades mucosal epithelial cells of the distal small bowel and colon. In an elegant series of experiments, one plasmid and three sites on the bacterial genome necessary for virulence traits of shigellae, including invasion of HeLa cells, mucosal inflammation, a positive Sereny result, and



**Figure 2.** Cecal tissue taken from a rabbit with enteroadherent *E. coli* strain RDEC-1 diarrhea. The tissue was treated with ferritin-conjugated RDEC-1-specific IgG but was not stained after embedment. The ferritin-labeled bacteria are closely associated with the lumenal surface of a mucosal epithelial cell that has been denuded of microvilli. Several of the bacteria are cupped with the pedestal-like structures common in tissues infected with enteroadherent *E. coli*. Bar = 1  $\mu$ .

production of fluid in the rabbit ileal loop by *Shigella* (*flexneri*) have been localized [78,79]. When these genes are instilled in an *E. coli* K12 strain, it exhibits all of the virulence properties of a fully virulent *Shigella*. The genes necessary for invasion of HeLa cells are located on a large 140 megadalton plasmid that causes minicells to synthesize outer membrane proteins, which by inference are important in HeLa cell invasion [80]. The *his* region of the bacterial genome, which codes, among other things, for O antigen synthesis, is important for mucosal inflammation [79]. Studies by Wantanabe et al [81,82] indicate that a small plasmid, which codes for a 41,000 megadalton protein involved in the formation of O side chains, is important for production of a positive Sereny result by a *Shigella flexneri* type 1 strain. Together, these latter data confirm a role for surface polysaccharides in virulence of shigellae but do not indicate a role in adherence. Shigellae have not been shown to possess any type of pilus protein that might be important in adherence. Thus, although the stages of pathogenesis of shigellosis have been clearly delineated, the structures relevant to each stage of pathogenesis have not been determined.

Salmonellae adhere to mucosal epithelium in the process of invading it, a process that has been well described using electron microscopic techniques [83]. Microvillus border and epithelial cells are altered, although not se-

verely, in the process of invasion. The bacterium prefers the Peyer's patch [84,85], as does the rabbit strain of enteroadherent *E. coli* [57]. Invasion and adherence are associated with a 60 megadalton plasmid [86]. *Salmonella typhimurium* exhibits type 1 pili (mannose-sensitive) that are associated with an increased infectivity in the mouse [87]. Salmonellae can adhere to Henle cells or adhere to and invade HeLa cells in tissue culture, a characteristic that is mannose-resistant and not thought to be due to pili [88–90]. The surface features involved in adherence and invasion of *Salmonella* are not known. Vi antigen, a surface polysaccharide of *Salmonella typhi* that interferes with the ability of anti-O antigen serum to react with the O antigen [91] (a similar antigen is a feature of enteropathogenic serotypes of *E. coli*), increases the virulence of *S. typhi* strains for human volunteers in an unknown fashion [92].

#### BACTERIAL ENTEROTOXINS

Adherence phenomena are, in general, species-restricted. In contrast, enterotoxins show no preference concerning species, a characteristic that has greatly facilitated their study. *Vibrio cholerae* and, to a lesser extent, enterotoxigenic *E. coli* synthesize enterotoxin material in such quantity that the enterotoxin activity can be easily detected in culture supernatant. It is uncertain whether the

toxins are actively excreted or released into the medium with membrane material [93]. Cholera toxin has been highly purified, has a molecular weight of approximately 92,000 daltons and is known to be composed of three subunits, A1, A2 and B. Subunit A1 is an enzyme and ADP-ribosylates GTP-regulatory protein, a component of the adenylate cyclase system. The result is an increase in intracellular cAMP levels, which elicit the specific biologic response of the cell exposed to the toxin. Subunit A2 plays a role in toxin internalization. The B subunit, of which there are five per molecule, is the ligand thought to be responsible for binding cholera toxin to GM1 ganglioside in the plasma membrane of cells (any cell). Labile toxin of *E. coli* is similar to cholera toxin in most respects. The effect of both toxins on intestinal villus cells is the inhibition of sodium absorption and hence of chloride and water. In crypt cells, sodium secretion is increased, with the consequent loss of chloride and water. Details of this can be found in several reviews [94–97].

Stable toxin ST of *E. coli*, in contrast to cholera toxin and *E. coli* labile toxin, is not an enzyme and has a molecular weight of about 2,000 daltons [98]. It exists in two or perhaps more forms, STa and STb [99–101]. STa, which is synthesized by both human and animal strains and has been sequenced, acts by stimulating guanylate cyclase, which produces an increase in cGMP [101–105]. ST is specific for intestinal cells, where it inhibits absorption of fluid and electrolytes. It appears to produce some chloride secretion as well [105]. STb-producing strains are usually of porcine origin. The mode of action of STb, which is different from that of STa, is unknown.

*Salmonella* infection results in an elevation of cAMP in gut tissues, but it is not clear whether the increase is due to an enterotoxin or to the effects of invasion [106,107]. Studies of *Salmonella* lysates indicate that both cytotoxins and enterotoxins are present [108–110], but published data are conflicting as to their nature.

Shiga toxin, first recognized as a toxin of *Shigella dysenteriae* 1 in 1903 [111], is a protein toxin that is cytotoxic for HeLa cells and Vero cells, neurotoxic in mice and rabbits, and enterotoxic in the rabbit ileal loop [112], and has been highly purified in several laboratories [113–116]. In contrast to cholera toxin, Shiga toxin has an adverse effect on epithelial cells when injected into the rabbit ileal loop [117]. The molecular weight of the native toxin is probably in the range of 70,000 daltons [114,116]. Crude data suggest the possibility of an A subunit with an approximate molecular weight of 30,000 daltons and a much smaller B subunit [118]. The toxin binds to a glycoprotein on the (HeLa) cell surface, is translocated into the cell in an energy-dependent step, and binds to and inactivates the 60s ribosomal subunit [119–121].

The exact role of this toxin in *Shigella* diarrhea remains uncertain. However, in monkeys given *S. flexneri* by mouth, diarrhea developed before dysentery and was

**TABLE II Bacterial Strains Containing Shiga Toxin**

No detectable Shiga toxin
enteropathogenic <i>E. coli</i> (1)*
enterotoxigenic <i>E. coli</i> (1)
<i>Pseudomonas aeruginosa</i> (1)
Trace amount of Shiga toxin
<i>E. coli</i> K12 (1)
<i>E. coli</i> , normal flora (1)
Low to moderate amount of Shiga toxin
<i>S. typhimurium</i> (1)
<i>E. coli</i> , diarrhea associated, untyped (1)
<i>E. coli</i> , 0143, diarrhea associated (1)
enterotoxigenic <i>E. coli</i> (2)
enteropathogenic <i>E. coli</i> (2)
<i>S. flexneri</i> 2a, strain M4243 (1)
Large amount of Shiga toxin
enteropathogenic <i>E. coli</i> , 026 and 0157,
bloody diarrhea strains (4)
<i>E. coli</i> S-22-1 0103, diarrhea associated (1)
<i>S. dysenteriae</i> , type 1, strain 60R (1)
01 <i>V. cholerae</i> (5/10 strains tested)
Non-01 <i>V. cholerae</i> (1)
<i>Vibrio parahaemolyticus</i> (3)

Adapted from [124–126].

\*Numbers in parentheses are numbers of strains tested.

accompanied by jejunal colonization but not invasion, and there was secretion of water into the jejunum [122]. When the bacteria were given directly into the cecum, dysentery occurred, but there was no diarrhea, and water transport was normal in the jejunum [123]. These two observations comprise the only evidence for a role of Shiga toxin in shigellosis, but it is believed that such a role exists.

In a series of publications, O'Brien and co-workers [124–126] have shown that a wide variety of bacteria that cause diarrhea also produce Shiga toxin (Table II). In fact, only three of the many strains of bacteria tested thus far have not produced toxin. The key to being able to find the toxin in lysates of so many different bacteria was an observation by Dubos and Geiger [128] in 1946 that inorganic iron in the medium decreased the yield of Shiga toxin. When O'Brien and LaVeck [127] removed iron from the medium, the Shiga toxin was more easily detected. The question of the precise role for the Shiga toxin in bacterial diarrhea is critical if the full impact of the work of O'Brien and colleagues is to be known, especially since many of the bacteria listed in Table II produce other potent enterotoxins, including cholera toxin.

Hemorrhagic colitis, due to *E. coli* serogroup 0157 [129,130], and hemolytic-uremic syndrome, associated with infection with several *E. coli* serogroups, but especially serogroups 026 and 0157 [131,132], are two syndromes in which it seems highly likely that Shiga toxin will be important in pathogenesis. These *E. coli* produce large amounts of Shiga toxin (Table II). It is worth noting that *E. coli* 026 was initially reported to synthesize Vero cell toxin [133,134] as was the *E. coli* associated with hemolytic-

uremic syndrome. In fact, the Vero cell cytotoxin could easily be detected in the feces [131]. It is now thought that the Vero and Shiga toxins are one and the same [125,132].

Some years ago, lysates of several enteropathogenic *E. coli* serogroups were said to cause net transport of water into the lumen in a rat jejunal perfusion assay [135]. The same *E. coli* was known to cause diarrhea in humans [136]. The question that must now be answered is whether the jejunal perfusion assay measures Shiga toxin or some other, as yet uncharacterized, toxin.

### PROTOZOAN DIARRHEA

*Entamoeba histolytica* dysentery is the best understood of the protozoan diarrheas. The only histopathologic study of in vivo interaction of *E. histolytica*-mucosal epithelial cell interaction is an ultrastructural study in germ-free guinea pigs inoculated intracecally with *E. histolytica* and enteric flora of a human patient with acute amebic colitis [137]. In that model, with its obvious limitations, the amebas approached the epithelial cell, the microvillus border disappeared, the epithelial cell became detached from the lamina propria and adjoining epithelial cells, and the amebas invaded by passing between the detached epithelial cells. Guerrant and colleagues [138,139] have examined the in vitro interaction of axenic amebas with Chinese hamster ovary cells and have described several stages in the interaction: adherence, extracellular cytolysis of the Chinese hamster ovary cell, and phagocytosis of the lysed cell. Adherence but not phagocytosis was inhibited by *N*-acetyl-D-galactosamine. The work of other investigators corroborates these studies [140–142].

*E. histolytica* possesses a cytotoxin, probably a protease enzyme, the quantity of which is correlated with virulence [143–146]. It has been suggested that this material is important in the tissue destruction produced by the invading amebas. *E. histolytica* also has enterotoxic activity. Some type of enterotoxic activity has been described in amebic preparations in three different laboratories, including our own [143,147,148].

Our understanding of the pathogenesis of *Giardia* infections is too sketchy to be worthy of comment. The same is true for the *Cryptosporidium*, except that it has a histopathologic picture similar to that of enteroadherent *E. coli*. It adheres closely to mucosal epithelial cells in areas lacking microvillus border in patients with the acquired immune deficiency syndrome [149].

### RISK FACTORS FOR INFECTIOUS DIARRHEA

Risk factors may be categorized as environmental or host-specific in origin. The impact of the environment reflects the fact that the usual route of spread of diarrheal diseases is fecal-oral. The spread may be from person to person or there may be an intermediate step, such as contamination of water or food with infected feces. Living

conditions, which often reflect socioeconomic conditions, have a major impact on diarrheal attack rates. A recent study in Brazil identified the unavailability of sanitary facilities and crowding in the poorer families as particular risk factors [150]. The quality and quantity of water are also quite important [151]. Locale and season of the year influence the prevalence and attack rates for specific pathogens. For example, enterotoxigenic *E. coli* is more common in the tropics in the summer, whereas rotavirus diarrhea is more common in temperate zones in the fall and winter.

Host behavioral patterns can be quite important and do not always reflect poor personal hygiene due to lack of education. For example, amebiasis is more common among male homosexuals [152]. Firemen and policemen scuba diving off Long Island had a high incidence of protozoan diarrheas, probably due to diving in polluted waters without a mask that completely covered the face [153].

Host physical factors may be specific or nonspecific. Decreased gastric acidity increases the risk for infectious diarrhea because acid conditions have an adverse impact on bacterial growth [1]. Malnutrition is known to increase diarrheal attack rates [154,155].

Specific host factors include receptor and immunologic status. Enterotoxigenic *E. coli* strains show restricted species specificity. Animal enterotoxigenic *E. coli* strains are not known to infect humans. Human enterotoxigenic *E. coli* strains do not cause diarrhea in animals without major manipulation of the animal host. Species specificity is presumably due to the presence of specific receptors on mucosal epithelial cells. Specificity can vary within a species. Some strains of pigs have a decreased affinity for the K88 adherence ligand that is reflected in a decreased diarrheal attack rate [156]. On the other hand, host species is not as important for some pathogens, such as *Salmonella*. The presence of receptors may also be age-related. The RDEC-1 enteroadherent *E. coli* does not adhere to ileal brush borders until the rabbits are 20 days old [157].

Finally, immunologic status is important. The susceptibility of weanling animals and human infants to infectious diarrhea is well known and is thought to be due to the lack of protective mucosal antibody that, prior to weaning, was supplied in the maternal milk [150,158,159]. Severe immunosuppression, whether due to immunosuppressive drugs or infection, is a recognized risk factor. Bone marrow transplant recipients are susceptible to a variety of infectious agents that produce diarrhea [160]. Debilitating cryptosporidial diarrhea, heretofore unknown, is common among patients with the acquired immune deficiency syndrome [149].

### THE FUTURE

It is obvious that there has been a dramatic resurgence of interest in pathogenesis of infectious diarrheas. The interaction of infectious agents with mucosal surfaces is a

complex process that easily frustrates attempts to unlock its secrets. The search for answers will be best served by using animal models in which the pathogen being studied is host-specific, an approach that will require an aggressive search for additional small animal models of infectious diarrhea. Studies in animal models are admittedly difficult, but the results are more than worth the effort. The use of modern genetic techniques to alter existing etiologic agents or to construct new infectious agents will be especially helpful in determining the precise role of individual virulence factors among infectious agents.

## ACKNOWLEDGMENT

I would like to acknowledge Karen Temple for preparation of Figure 1 and L.R. Inman, Ph.D., for providing the electron micrograph and valuable help with preparation of this manuscript. I would also like to acknowledge Dr. Samuel B. Formal, who, since 1976, has guided me in my investigations of the pathogenesis of bacterial diarrhea and whose name graces so many of the articles referred to herein. Finally, I would like to thank Dr. Herbert L. DuPont for the opportunity to present my views and for waiting so long to get them.

## REFERENCES

- Gianella RA, Broitman SA, Zarncheck N: Influence of gastric acidity on bacterial and parasitic enteric infections: a perspective. *Ann Intern Med* 1973; 78: 271-276.
- Formal SB, Abrams GD, Schneider H, Sprinz H: Experimental Shigella infections. VI. Role of the small intestine in an experimental infection in guinea pigs. *J Bacteriol* 1963; 85: 119-125.
- Dietsch JM, Westergaard H: The effect of unstirred water layers on various transport processes in the intestine. In: Csaky TZ, ed. *Intestinal absorption*. New York: Raven Press, 1975; 197-207.
- Hounsell EF, Feizi T: Gastrointestinal mucins: structures and antigenicities of their carbohydrate chains in health and disease. *Med Biol* 1982; 60: 227-236.
- Bishop RF, Davidson GP, Holmes IH, Ruck BJ: Virus particles in epithelial cells in duodenal mucosa from children with acute nonbacterial gastroenteritis. *Lancet* 1973; II: 1281-1283.
- Suzuki H, Konno T: Reovirus-like particles in jejunal mucosa of a Japanese infant with acute infectious non-bacterial gastroenteritis. *Tohoku J Exp Med* 1975; 115: 199-211.
- Takeuchi A, Binn LN, Jervis HR, et al: Electron microscope study of experimental enteric infection in neonatal dogs with a canine coronavirus. *Lab Invest* 1976; 34: 539-549.
- Davidson GP, Gall DG, Petric M, Butler DG, Hamilton JR: Human rotavirus enteritis induced in conventional piglets: intestinal structure and transport. *J Clin Invest* 1977; 60: 1402-1409.
- Shepherd RW, Gall DG, Butler DG, Hamilton JR: Determinants of diarrhea in viral enteritis: the role of ion transport and epithelial changes in the ileum in transmissible gastroenteritis in piglets. *Gastroenterology* 1979; 76: 20-24.
- Keenan KP, Jervis HR, Marchwicki RH, Binn LN: Intestinal infection of neonatal dogs with canine coronavirus 1-71: studies by virologic, histologic, histochemical, and immunofluorescent techniques. *Am J Vet Res* 1976; 37: 247-256.
- Snodgrass DR, Angus KW, Gray EW: Rotavirus infection in lambs: pathogenesis and pathology. *Arch Virol* 1977; 55: 263-274.
- Schreiber DS, Blacklow NR, Trier JS: The mucosal lesion of the proximal small intestine in acute infectious nonbacterial gastroenteritis. *N Engl J Med* 1973; 288: 1318-1323.
- Kerzner B, Kelly MH, Gall DG, Butler DG, Hamilton JR: Transmissible gastroenteritis: sodium transport in the intestinal epithelium during the course of viral enteritis. *Gastroenterology* 1977; 72: 457-461.
- Dolin R, Levy AG, Wyatt RG, Thornhill TS, Gardner JD: Viral gastroenteritis induced by the Hawaii agent. Jejunal histopathology and serologic response. *Am J Med* 1975; 59: 761-768.
- Agus SG, Dolin R, Wyatt RG, Tousimis AJ, Northrup RS: Acute infectious nonbacterial gastroenteritis: intestinal histopathology: histologic and enzymatic alterations during illness produced by the Norwalk agent in man. *Ann Intern Med* 1973; 79: 18-25.
- Blacklow NR, Cukor G: Norwalk virus: a major cause of epidemic gastroenteritis. *Am J Public Health* 1982; 72: 1321-1323.
- Attridge SR, Rowley D: The role of the flagellum in the adherence of *Vibrio cholerae*. *J Infect Dis* 1983; 147: 864-872.
- Attridge SR, Rowley D: The specificity of *Vibrio cholerae* adherence and the significance of the slime agglutinin as a second mediator of in vitro attachment. *J Infect Dis* 1983; 147: 873-881.
- Finkelstein RA, Boesman-Finkelstein M, Holt P: *Vibrio cholerae* hemagglutinin/lectin/protease hydrolyzes fibronectin and ovomucin: FM Burnet revisited. *Proc Natl Acad Sci USA* 1983; 80: 1092-1095.
- Guentzel MN, Berry LJ: Motility as a virulence factor for *Vibrio cholerae*. *Infect Immun* 1975; 11: 890-897.
- Jones GW, Abrams GD, Freter R: Adhesive properties of *Vibrio cholerae*: adhesion to isolated rabbit brush border membranes and haemagglutinating activity. *Infect Immun* 1976; 14: 232-239.
- Jones GW, Freter R: Adhesive properties of *Vibrio cholerae*: nature of the interaction with isolated rabbit brush border membranes and human erythrocytes. *Infect Immun* 1976; 14: 240-245.
- Sheehy TW, Sprinz H, Augerson WS, Formal SB: Laboratory *Vibrio cholerae* infection in the United States. *JAMA* 1966; 197: 321-326.
- Elliott HL, Carpenter CJC, Sack RB, Yardley JH: Small bowel morphology in experimental canine cholera: a light and electron microscopic study. *Lab Invest* 1970; 22: 122-120.
- Chen H-C, Reyes V, Fresh JW: An electron microscopic study of the small intestine in human cholera. *Virchows Arch* 1971; 7: 236-259.
- Chan R, Acres SD, Costerton JW: Use of specific antibody to demonstrate glycocalyx, K99 pili, and the spatial relationships of K99+ enterotoxigenic *Escherichia coli* in the ileum of colostrum-fed calves. *Infect Immun* 1982; 37: 1170-1180.
- Smith HW, Linggood MA: Observations on the pathogenic properties of the K88, Hly and Ent plasmids of *Escherichia coli* with particular reference to porcine diarrhoea. *J Med Microbiol* 1971; 4: 467-485.
- Duguid JP, Smith IW, Dempster G, Edmunds PN: Non-flagellar filamentous appendages ("fimbriae") and haemagglutinating activity in *Bacterium coli*. *J Pathol Bacteriol* 1955; 70: 335-348.
- Brinton CC Jr: Non-flagellar appendages of bacteria. *Nature* 1959; 183: 782-786.
- Brinton CC Jr: Contributions of pili to the specificity of the bacterial surface and a unitary hypothesis of conjugal infectious heredity. In: Davis BD, Warren L, eds. *The specificity of cell surfaces*. Englewood Cliffs, New Jersey: Prentice-Hall, 1976; 37-70.



31. Brinton CC Jr: The piliation phase syndrome and the uses of purified pili in disease control. Proceedings of the XIIIth joint US-Japan conference on cholera (DHEW pub. no. NIH-78-1590). Bethesda, Maryland: National Institutes of Health, 1978; 33-70.
32. Evans DG, Silver RP, Evans DJ Jr, Chase DG, Gorbach SL: Plasmid-controlled colonization factor associated with virulence in *Escherichia coli* enterotoxigenic for humans. *Infect Immun* 1975; 12: 656-667.
33. Orskov I, Orskov F, Sojka WJ, Leach JM: Simultaneous occurrence of *Escherichia coli* B and L antigens in strains from diseased swine. *Acta Pathol Microbiol Scand* 1961; 53: 404-422.
34. Orskov I, Orskov F, Smith HW, Sojka WJ: The establishment of K99, a thermolabile, transmissible *Escherichia coli* K antigen, previously called "Kco," possessed by calf and lamb enteropathogenic strains. *Acta Pathol Microbiol Scand (Microbiol Immunol)* 1975; 83: 31-36.
35. Smith HW, Huggins MB: The influence of plasmid-determined and other characteristics of enteropathogenic *Escherichia coli* on their ability to proliferate in the alimentary tracts of piglets, calves and lambs. *J Med Microbiol* 1977; 11: 471-492.
36. Moon HW, Nagy B, Isaacson RE, Orskov I: Occurrence of K99 antigen on *Escherichia coli* isolated from pigs and colonization of pig ileum by K99+ enterotoxigenic *E. coli* from calves and pigs. *Infect Immun* 1977; 15: 614-620.
37. Nagy B, Moon HW, Isaacson RE: Colonization of porcine small intestine by *Escherichia coli*: ileal colonization and adhesion by pig enteropathogens that lack K88 antigen and by some acapsular mutants. *Infect Immun* 1976; 13: 1214-1220.
38. Nagy B, Moon HW, Isaacson RE: Colonization of porcine intestine by enterotoxigenic *Escherichia coli*: selection of pilated forms in vivo, adhesion of pilated forms to epithelial cells in vitro, and incidence of a pilus antigen among porcine enteropathogenic *E. coli*. *Infect Immun* 1977; 16: 344-352.
39. Morris JA, Thorns C, Scott AC, Sojka WJ, Wells GA: Adhesion in vitro and in vivo associated with an adhesive antigen (F41) produced by a K99 mutant of the reference strain *Escherichia coli* B41. *Infect Immun* 1982; 36: 1146-1153.
40. Morris JA, Thorns CJ, Wells GAH, Scott AC, Sojka WJ: The production of F41 fimbriae by piglet strains of enterotoxigenic *Escherichia coli* that lack K88, K99 and 987P fimbriae. *J Gen Microbiol* 1983; 129: 2753-2759.
41. Morris JA, Wells GAH, Scott AC, Sojka WJ: Colonisation of the small intestine of lambs by an enterotoxigenic *Escherichia coli* producing F41 fimbriae. *Vet Rec* 1983; 113: 471.
42. To SC: F41 antigen among porcine enterotoxigenic *Escherichia coli* lacking K88, K99, and 987P pili. *Infect Immun* 1984; 43: 549-554.
43. Evans DG, Evans DJ Jr, Tjoa WS, DuPont HL: Detection and characterization of colonization factor of enterotoxigenic *Escherichia coli* isolated from adults with diarrhea. *Infect Immun* 1978; 19: 727-736.
44. Evans DG, Evans DJ Jr: New surface-associated heat-labile colonization factor antigen (CFA/II) produced by enterotoxigenic *Escherichia coli* of serogroups O6 and O8. *Infect Immun* 1978; 21: 638-647.
45. Satterwhite TK, DuPont HL, Evans DG, Evans DJ Jr: Role of *Escherichia coli* colonisation factor antigen in acute diarrhoea. *Lancet* 1978; II: 181-184.
46. Wilson MR, Hohmann AW: Immunity to *Escherichia coli* in pigs: adhesion of enteropathogenic *Escherichia coli* to isolated intestinal epithelial cells. *Infect Immun* 1974; 10: 776-782.
47. Burrows MR, Sellwood R, Gibbons RA: Haemagglutinating and adhesive properties associated with the K99 antigen of bovine strains of *Escherichia coli*. *J Gen Microbiol* 1976; 96: 269-275.
48. Isaacson, RE, Fusco PC, Brinton CC, Moon HW: In vitro adhesion of *Escherichia coli* to porcine small intestinal epithelial cells: Pili as adhesive factors. *Infect Immun* 1978; 21: 392-397.
49. Cheney CP, Boedeker EC: Adherence of an enterotoxigenic *Escherichia coli* strain, serotype 078:H11, to purified human intestinal brush borders. *Infect Immun* 1983; 39: 1280-1284.
50. Knutton S, Lloyd DR, Candy DCA, McNeish AS: In vitro adhesion of enterotoxigenic *Escherichia coli* to human intestinal epithelial cells from mucosal biopsies. *Infect Immun* 1984; 44: 514-518.
51. Bergman JM, Evans DG, Mandell GL, Sullivan JA, Salit IE, Guerrant RL: Attachment of *E. coli* to human intestinal epithelial cells: a functional in vitro test for intestinal colonization factor. *Trans Assoc Am Physicians* 1978; 91: 80-89.
52. Wadstrom T, Faris A, Freer J, Habte D, Hallberg D, Ljungh A: Hydrophobic surface properties of enterotoxigenic *E. coli* (ETEC) with different colonization factors (CFA/I, CFA/II, K88 and K99) and attachment to intestinal epithelial cells. *Scand J Infect Dis* 1980; suppl 24: 148-153.
53. Thorne GM, Deneke CF, Gorbach SL: Hemagglutination and adhesiveness of toxigenic *Escherichia coli* isolated from humans. *Infect Immun* 1979; 23: 690-699.
54. Deneke CF, McGowan K, Thorne GM, Gorbach SL: Attachment of enterotoxigenic *Escherichia coli* to human intestinal cells. *Infect Immun* 1983; 39: 1102-1106.
55. Deneke CF, Thorne GM, Gorbach SL: Serotypes of attachment pili of enterotoxigenic *Escherichia coli* isolated from humans. *Infect Immun* 1981; 32: 1254-1260.
56. Deneke CF, McGowan K, Larson AD, Gorbach SL: Attachment of human and pig (K88) enterotoxigenic *Escherichia coli* strains to either human or porcine small intestinal cells. *Infect Immun* 1984; 45: 522-524.
57. Inman LR, Cantey JR: Specific adherence of *Escherichia coli* (strain RDEC-1) to membranous (M) cells of the Peyer's patch in *Escherichia coli* diarrhea in the rabbit. *J Clin Invest* 1983; 71: 1-8.
58. Moon HW, Whipp SC, Argenzio RA, Levine MM, Giannella RA: Attaching and effacing activities of rabbit and human enteropathogenic *Escherichia coli* in pig and rabbit intestines. *Infect Immun* 1983; 41: 1340-1351.
59. Staley TE, Jones EW, Corley LD: Attachment and penetration of *Escherichia coli* into intestinal epithelium of the ileum in newborn pigs. *Am J Pathol* 1969; 56: 371-392.
60. Cantey JR, Blake RK: Diarrhea due to *Escherichia coli* in the rabbit: a novel mechanism. *J Infect Dis* 1977; 135: 454-462.
61. Takeuchi A, Inman LR, O'Hanley PD, Cantey JR, Lushbaugh WB: Scanning and transmission electron microscopic study of *Escherichia coli* 015 (RDEC-1) enteric infection in rabbits. *Infect Immun* 1978; 19: 686-694.
62. Cantey JR, Lushbaugh WB, Inman LR: Attachment of bacteria to intestinal epithelial cells in diarrhea caused by *Escherichia coli* strain RDEC-1 in the rabbit: stages and role of capsule. *J Infect Dis* 1981; 143: 219-230.
63. Ulshen MH, Rollo JL: Pathogenesis of *Escherichia coli* gastroenteritis in man—another mechanism. *N Engl J Med* 1980; 302: 99-101.
64. Rothbaum R, McAdams AJ, Giannella R, Partin JC: A clinicopathologic study of enterocyte-adherent *Escherichia coli*: a cause of protracted diarrhea in infants. *Gastroenterology* 1982; 83: 441-454.
65. Clausen CR, Christie DL: Chronic diarrhea in infants caused by adherent enteropathogenic *Escherichia coli*. *J Pediatr* 1982; 100: 358-361.
66. Drucker MM, Polliack A, Yeivin R, Sacks TG: Immunofluorescent demonstration of enteropathogenic *Escherichia coli* in tissues of infants dying with enteritis. *Pediatrics* 1970; 46: 855-864.
67. Cravioto A, Gross RJ, Scotland SM, Rowe B: An adhesive factor found in strains of *Escherichia coli* belonging to the tradi-

- tional infantile enteropathogenic serotypes. *Curr Microbiol* 1979; 3: 95–99.
68. Scaletsky ICA, Silva MLM, Trabulsi LR: Distinctive patterns of adherence of enteropathogenic *Escherichia coli* to HeLa cells. *Infect Immun* 1984; 45: 534–536.
  69. Lacroix J, Delage G, Gosselin F, Chicoine L: Severe protracted diarrhea due to multiresistant adherent *Escherichia coli*. *Am J Dis Child* 1984; 138: 693–696.
  70. Mathewson JJ, DuPont JL, Morgan DL, Thornton SA, Ericsson CD: Enteroadherent *Escherichia coli* associated with travelers' diarrhoea. *Lancet* 1983; i: 1048.
  71. Cheney CP, Formal SB, Schad PA, Boedeker EC: Genetic transfer of a mucosal adherence factor (R1) from an enteropathogenic *Escherichia coli* strain into a *Shigella flexneri* strain and the phenotypic suppression of this adherence factor. *J Infect Dis* 1983; 147: 711–723.
  72. Cheney CP, Boedeker EC, Formal SB: Quantitation of the adherence of an enteropathogenic *Escherichia coli* to isolated rabbit intestinal brush borders. *Infect Immun* 1979; 26: 736–743.
  73. Scotland SM, Richmond JE, Rowe B: Adhesion of enteropathogenic strains of *Escherichia coli* (EPEC) to Hep-2 cells is not dependent on the presence of fimbriae. *FEMS Microbiol Lett* 1983; 20: 191–195.
  74. Baldini MM, Kaper JB, Levine MM, Candy DCA, Moon HW: Plasmid-mediated adhesion in enteropathogenic *Escherichia coli*. *J Pediatr Gastroenterol Nutr* 1983; 2: 534–538.
  75. Formal SB, Dammin GJ, LaBrec EH, Schneider H: Experimental shigella infections: characteristics of a fatal infection produced in guinea pigs. *J Bacteriol* 1958; 75: 604–610.
  76. Labrec EH, Schneider H, Magnani TJ, Formal SB: Epithelial cell penetration as an essential step in the pathogenesis of bacillary dysentery. *J Bacteriol* 1964; 88: 1503–1518.
  77. Takeuchi A, Formal SB, Sprinz H: Experimental acute colitis in the Rhesus monkey following peroral infection with *Shigella flexneri*: an electron microscope study. *Am J Pathol* 1968; 52: 503–529.
  78. Sansonetti P, Formal SB, Hale TL, Kopecko DJ: Bases genetiques de la penetration de *Shigella flexneri* dans les cellules epitheliales. *Ann Immunol* 1981; 132D: 183–189.
  79. Sansonetti PJ, Hale TL, Dammin GJ, Kapfer C, Collins HH Jr, Formal SB: Alterations in the pathogenicity of *Escherichia coli* K-12 after transfer of plasmid and chromosomal genes from *Shigella flexneri*. *Infect Immun* 1983; 39: 1392–1402.
  80. Hale TL, Sansonetti PJ, Schad PA, Austin S, Formal SB: Characterization of virulence plasmids and plasmid-associated outer membrane proteins in *Shigella flexneri*, *Shigella sonnei*, and *Escherichia coli*. *Infect Immun* 1983; 40: 340–350.
  81. Watanabe H, Timmis KN: A small plasmid in *Shigella dysenteriae* 1 specifies one or more functions essential for O antigen production and bacterial virulence. *Infect Immun* 1984; 43: 391–396.
  82. Watanabe H, Nakamura A, Timmis KN: Small virulence plasmid of *Shigella dysenteriae* 1 strain W30864 encodes a 41,000-dalton protein involved in formation of specific lipopolysaccharide side chains of serotype 1 isolates. *Infect Immun* 1984; 46: 55–63.
  83. Takeuchi A: Electron microscope observations on penetration of the gut epithelial barrier by *Salmonella typhimurium*. In: Schlessinger D, ed. *Microbiology*. Washington: American Society for Microbiology, 1975; 174–181.
  84. Hohmann AW, Schmidt G, Rowley D: Intestinal colonization and virulence of *Salmonella* in mice. *Infect Immun* 1978; 22: 763–770.
  85. Carter P, Collins F: The route of enteric infection in normal mice. *J Exp Med* 1974; 139: 1189–1203.
  86. Jones GW, Rabert DK, Svinarich DM, Whitfield HJ: Association of adhesive, invasive, and virulent phenotypes of *Salmonella typhimurium* with autonomous 60-megadalton plasmids. *Infect Immun* 1982; 38: 476–486.
  87. Duguid JP, Darekar MR, Wheeler DWF: Fimbriae and infectivity in *Salmonella typhimurium*. *J Med Microbiol* 1976; 9: 459–473.
  88. Gianella RA, Washington O, Gemski P, Formal SB: Invasion of HeLa cells by *Salmonella typhimurium*: a model for study of invasiveness of *Salmonella*. *J Infect Dis* 1973; 128: 69–75.
  89. Jones GW, Richardson LA: The attachment to, and invasion of HeLa cells by *Salmonella typhimurium*: the contribution of mannose-sensitive and mannose-resistant haemagglutinating activities. *J Gen Microbiol* 1981; 127: 361–370.
  90. Mintz CS, Cliver DO, Deibel RH: Attachment of *Salmonella* to mammalian cells in vitro. *Can J Microbiol* 1983; 29: 1731–1735.
  91. Felix A, Pitt RM: The pathogenic and immunogenic activities of *Salmonella typhi* in relation to its antigenic constituents. *J Hyg (Camb)* 1915; 49: 92–110.
  92. Hornick RB, Greisman SE, Woodward TE, DuPont HL, Dawkins AT, Snyder MJ: Typhoid fever: pathogenesis and immunologic control. *N Engl J Med* 1970; 283: 686–691.
  93. Gankema H, Wensink J, Guinee PAM, Jansen WH, Witholt B: Some characteristics of the outer membrane material released by growing enterotoxigenic *Escherichia coli*. *Infect Immun* 1980; 29: 704–713.
  94. Middlebrook JL, Dorland RB: Bacterial toxins: cellular mechanisms of action. *Microbiol Rev* 1984; 48: 199–221.
  95. Finkelstein RA: Cholera. *CRC Crit Rev Microbiol* 1973; 2: 553–623.
  96. Gill DM: Mechanism of action of cholera toxin. *Adv Cyclic Nucleotide Res* 1977; 8: 85–118.
  97. Field M: Model of action of enterotoxins from *Vibrio cholerae* and *Escherichia coli*. *Rev Infect Dis* 1979; 1: 918–926.
  98. Aimoto S, Takao T, Shimonishi Y, et al: Amino-acid sequence of heat-stable enterotoxin produced by human enterotoxigenic *Escherichia coli*. *Eur J Biochem* 1982; 129: 257–263.
  99. Burgess MN, Bywater RJ, Cowley CM, Mullan NA, Newsome PM: Biological evaluation of a methanol-soluble, heat-stable *Escherichia coli* enterotoxin in infant mice, pigs, rabbits, and calves. *Infect Immun* 1978; 21: 526–531.
  100. Olson E, Soderland O: Comparison of different assays for definition of heat-stable enterotoxigenicity of *Escherichia coli* porcine strains. *J Clin Microbiol* 1980; 11: 6–15.
  101. Rao MR, Orellana SA, Field M, Robertson DC, Giannella RA: Comparison of the biological actions of three purified heat-stable enterotoxins: effects on ion transport and guanylate cyclase activity in rabbit ileum in vitro. *Infect Immun* 1981; 33: 165–170.
  102. Rao MC, Guandalini S, Smith PL, Field M: Mode of action of heat-stable *Escherichia coli* enterotoxin. Tissue and subcellular specificities and role of cyclic GMP. *Biochim Biophys Acta* 1980; 632: 35–46.
  103. Guerrant RL, Hughes JM, Chang B, Robertson DC, Murad F: Activation of intestinal guanylate cyclase by heat-stable enterotoxin of *Escherichia coli*: studies of tissue specificity, potential receptors, and intermediates. *J Infect Dis* 1980; 142: 220–228.
  104. Giannella RA, Drake KW: Effect of purified *Escherichia coli* heat-stable enterotoxin on intestinal cyclic nucleotide metabolism and fluid secretion. *Infect Immun* 1979; 24: 19–23.
  105. Guandalini S, Rao MC, Smith PL, Field M: cGMP modulation of ileal ion transport: in vitro effects of *Escherichia coli* heat-stable enterotoxin. *Am J Physiol* 1982; 243: G36–G41.
  106. Giannella RA, Gots RE, Charney AN, Greenough WB, Formal SB: Pathogenesis of *Salmonella*-mediated intestinal fluid secretion: activation of adenylate cyclase and inhibition by indomethacin. *Gastroenterology* 1975; 69: 1238–1245.
  107. Peterson JW, Molina NC, Houston CW, Fader RC: Elevated cAMP in intestinal epithelial cells during experimental cholera and salmonellosis. *Toxicon* 1983; 21: 761–775.
  108. Sedlock DM, Koupal LR, Deibel RH: Production and partial purification of *Salmonella* enterotoxin. *Infect Immun* 1978;

- 20: 375–380.
109. Baloda SB, Faris A, Krovacek K, Wadstrom T: Cytotoxic enterotoxins and cytotoxic factors produced by *Salmonella enteritidis* and *Salmonella typhimurium*. *Toxicon* 1983; 21: 785–796.
  110. Koo FC, Peterson JW, Houston CW, Molina NC: Pathogenesis of experimental Salmonellosis: inhibition of protein synthesis by cytotoxin. *Infect Immun* 1984; 43: 93–100.
  111. Conradi H: Ueber losliche, durch aseptische Autolyse erhaltene Giftstoffe von Ruhr- und Typhus-bazillen. *Dtsch Med Wochenschr* 1903; 29: 26–28.
  112. Keusch GT, Donohur-Rolfe A, Jacewicz M: Shigella toxin(s): description and role in diarrhea and dysentery. *Pharmacol Ther* 1982; 15: 403–438.
  113. McIver J, Grady GF, Keusch GT: Production and characterization of exotoxin(s) of *Shigella dysenteriae* Type 1. *J Infect Dis* 1975; 131: 559–566.
  114. Olsnes S, Eiklid K: Isolation and characterization of *Shigella shigae* cytotoxin. *J Biol Chem* 1980; 255: 284–289.
  115. O'Brien AD, LaVeck GD, Griffin DE, Thompson MR: Characterization of *Shigella dysenteriae* 1 (Shiga) toxin purified by anti-Shiga toxin affinity chromatography. *Infect Immun* 1980; 30: 170–179.
  116. Brown JE, Griffin DE, Rothman SW, Doctor BP: Purification and biological characterization of Shiga toxin from *Shigella dysenteriae* 1. *Infect Immun* 1982; 36: 996–1005.
  117. Keusch GT, Grady GF, Takeuchi A, Sprinz H: The pathogenesis of *Shigella* diarrhea. II. Enterotoxin-induced acute enteritis in the rabbit ileum. *J Infect Dis* 1972; 126: 92–95.
  118. Olsnes S, Reisbig R, Eiklid K: Subunit structure of *Shigella* cytotoxin. *J Biol Chem* 1981; 256: 8732–8738.
  119. Keusch GT, Jacewicz M: Pathogenesis of *Shigella* diarrhea. VII. Evidence for a cell membrane toxin receptor involving  $\beta$ 14-linked N-acetyl-D-glucosamine oligomers. *J Exp Med* 1977; 146: 535–546.
  120. Jacewicz M, Keusch GT: Pathogenesis of *Shigella* diarrhea. VIII. Evidence for a translocation step in the cytotoxic action of Shiga toxin. *J Infect Dis* 1983; 148: 844–854.
  121. Reisbig R, Olsnes S, Eiklid K: The cytotoxic activity of *Shigella* toxin. Evidence for catalytic inactivation of the 60 S ribosomal subunit. *J Biol Chem* 1981; 256: 8739–8744.
  122. Rout WR, Formal SB, Giannella RA, Dammin GJ: Pathophysiology of *Shigella* diarrhea in the rhesus monkey: intestinal transport, morphological and bacteriological studies. *Gastroenterology* 1975; 68: 270–278.
  123. Kinsey MD, Formal SB, Dammin GJ, Giannella RA: Fluid and electrolyte transport in rhesus monkeys challenged intracally with *Shigella flexneri* 2a. *Infect Immun* 1976; 14: 368–371.
  124. O'Brien AD, LaVeck GD, Thompson MR, Formal SB: Production of *Shigella dysenteriae* type 1-like cytotoxin by *Escherichia coli*. *J Infect Dis* 1982; 146: 763–769.
  125. O'Brien AD, Lively TA, Chen ME, Rothman SW, Formal SB: *Escherichia coli* 0157:H7 strains associated with hemorrhagic colitis in the United States produce a *Shigella dysenteriae* 1 (Shiga) like cytotoxin. *Lancet* 1983; I: 702.
  126. O'Brien AD, Chen ME, Holmes RK: Environmental and human isolates of *Vibrio cholerae* and *Vibrio parahaemolyticus* produce a *Shigella dysenteriae* 1 (Shiga)-like cytotoxin. *Lancet* 1984; I: 77–78.
  127. O'Brien AD, LaVeck GD: Immunochemical and cytotoxic activities of *Shigella dysenteriae* 1 (Shiga) and Shiga-like toxins. *Infect Immun* 1982; 35: 1151–1154.
  128. Dubos RJ, Geiger JW: Preparation and properties of Shiga toxin and toxoid. *J Exp Med* 1946; 84: 143–156.
  129. Riley LW, Remis RS, Helgerson SD et al: Hemorrhagic colitis associated with a rare *Escherichia coli* serotype. *N Engl J Med* 1983; 308: 681–685.
  130. Outbreak of hemorrhagic colitis—Ottawa, Canada. *Morbidity Mortal Weekly Rep* 1983; 32: 133–134.
  131. Karmali MA, Steele BT, Petric M, Lim C: Sporadic cases of haemolytic-uraemic syndrome associated with faecal cytotoxin and cytotoxin-producing *Escherichia coli* in stools. *Lancet* 1983; I: 619–620.
  132. O'Brien AD, Lively TA, Chang TW, Gorbach SL: Purification of *Shigella dysenteriae* 1 (Shiga)-like toxin from *Escherichia coli* 0157:H7 strain associated with hemorrhagic colitis. *Lancet* 1983; II: 573.
  133. Konowalchuk J, Speirs JI, Stavric S: Vero response to a cytotoxin of *Escherichia coli*. *Infect Immun* 1977; 18: 775–779.
  134. Scotland SM, Day NP, Rowe B: Production of a cytotoxin affecting Vero cells by strains of *Escherichia coli* belonging to traditional enteropathogenic serogroups. *FEMS Microbiol Lett* 1980; 7: 15–17.
  135. Klipstein FA, Rowe B, Engert RF, Short HB, Gross RJ: Enterotoxigenicity of enteropathogenic serotypes of *Escherichia coli* isolated from infants with epidemic diarrhea. *Infect Immun* 1978; 21: 171–178.
  136. Levine MM, Bergquist EJ, Nalin DR, et al: *Escherichia coli* strains that cause diarrhoea but do not produce heat-labile or heat-stable enterotoxins and are non-invasive. *Lancet* 1978; I: 1119–1122.
  137. Takeuchi A, Phillips BP: Electron microscope studies of experimental *Entamoeba histolytica* infection in the guinea pig. I. Penetration of the intestinal epithelium by trophozoites. *Am J Trop Med Hyg* 1975; 24: 34–48.
  138. Ravdin JI, Croft BY, Guerrant RL: Cytopathogenic mechanisms of *Entamoeba histolytica*. *J Exp Med* 1980; 152: 377–390.
  139. Ravdin JI, Guerrant RL: Role of adherence in cytopathogenic mechanisms of *Entamoeba histolytica*. *J Clin Invest* 1981; 68: 1305–1313.
  140. McCaul TF, Poston RN, Bird RG: *Entamoeba histolytica* and *Entamoeba invadens*: chromium release from labeled human liver cells in culture. *Exp Parasitol* 1977; 43: 342–352.
  141. Knight R, Bird RG, McCaul RF: Fine structural changes at *Entamoeba histolytica* rabbit kidney cell (RK 13) interface. *Ann Trop Med Parasitol* 1974; 69: 197–202.
  142. Kobiler D, Mirelman D: Adhesion of *Entamoeba histolytica* trophozoites to monolayers of human cells. *J Infect Dis* 1981; 144: 539–546.
  143. Lushbaugh WB, Kairalla AB, Cantey JR, Hofbauer AF, Pittman FE: Isolation of a cytotoxin-enterotoxin from *Entamoeba histolytica*. *J Infect Dis* 1979; 139: 9–17.
  144. McGowan K, Deneke CF, Thorne GM, Gorbach SL: *Entamoeba histolytica* cytotoxin: purification, characterization, strain virulence, and protease activity. *J Infect Dis* 1982; 146: 616–625.
  145. Lushbaugh WB, Hofbauer AF, Pittman FE: Proteinase activities of *Entamoeba histolytica* cytotoxin. *Gastroenterology* 1984; 87: 17–27.
  146. Lushbaugh WB, Hofbauer AF, Kairalla AA, Cantey JR, Pittman FE: Relationship of cytotoxins of axenically cultivated *Entamoeba histolytica* to virulence. *Gastroenterology* 1984; 86: 1488–1495.
  147. Udezulu IA, Leitch GJ, Bailey GB: Use of indomethacin to demonstrate enterotoxic activity in extracts of *Entamoeba histolytica* trophozoites. *Infect Immun* 1982; 36: 795–801.
  148. McGowan K, Kane A, Asarkof N, et al: *Entamoeba histolytica* causes intestinal secretion: Role of serotonin. *Science* 1983; 221: 762–764.
  149. Pitlik SD, Fainstein V, Garza D, et al: Human cryptosporidiosis: spectrum of disease. Report of six cases and review of the literature. *Arch Intern Med* 1983; 143: 2269–2275.
  150. Guerrant RL, Kirchoff LV, Shields DS, et al: Prospective study of diarrheal illnesses in northeastern Brazil: patterns of disease, nutritional impact, etiologies, and risk factors. *J Infect Dis* 1983; 148: 986–997.

151. Hollister AC, Beck MD, Gittelsohn AM, Hemphill, EC: Influence of water availability on shigella prevalence in children of farm labor families. *Am J Public Health* 1955; 45: 354-362.
152. Schmerin MJ, Gelston A, Jones TC: Amebiasis. An increasing problem among homosexuals in New York City. *JAMA* 1977; 238: 1386-1387.
153. Gastrointestinal illness among scuba divers—New York City. *Morbidity and Mortality Weekly Report* 1983; 32: 576-577.
154. Scrimshaw NS, Taylor CE, Gordon JE: Interactions of nutrition and infection. Geneva; World Health Organization, 1968; 64-65.
155. Chandra RK, Newberne PM: Nutrition, immunity, and infection. Mechanisms of interactions. New York: Plenum Press, 1977, chapt 4.
156. Bijlsma IGW, de Nijs A, van der Meer C, Frik JF: Different pig phenotypes affect adherence of *Escherichia coli* to jejunal brush borders by K88ab, K88ac, or K88ad antigen. *Infect Immun* 1982; 37: 891-894.
157. Cheney CP, Boedeker EC. Rabbit mucosal receptors for an enteropathogenic *Escherichia coli* strain: appearance of bacterial receptor activity at weaning. *Gastroenterology* 1984; 87: 821-826.
158. Gordon JE, Chitkara ID, Wyon JB: Weanling diarrhea. *Am J Med Sci* 1963; 245: 345-377.
159. Mata LJ: The children of Santa Maria Cauque: a prospective field study of health and growth. Cambridge, Massachusetts: MIT Press, 1978.
160. Yolken RH, Bishop CA, Townsend TR, et al: Infectious gastroenteritis in bone-marrow-transplant recipients. *N Engl J Med* 1982; 306: 1009-1012.